DrugPatentWatch Database Preview
Details for Patent: 8,178,541
Which drugs does patent 8,178,541 protect, and when does it expire?
This patent has ninety-six patent family members in thirty-eight countries.
Summary for Patent: 8,178,541
Title: | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Abstract: | The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV). |
Inventor(s): | Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Warthausen, DE), Eckhardt; Matthias (Biberach, DE), Mark; Michael (Biberach, DE), Maier; Roland (Biberach, DE), Lotz; Ralf (Schemmerhofen, DE), Tadayyon; Mohammad (Neu-Ulm, DE) |
Assignee: | Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE) |
Application Number: | 12/143,128 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,178,541
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-001 | May 27, 2016 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA | ➤ Sign Up | |||
Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-002 | May 27, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA | ➤ Sign Up | |||
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) | ➤ Sign Up | |||
Boehringer Ingelheim | GLYXAMBI | empagliflozin; linagliptin | TABLET;ORAL | 206073-001 | Jan 30, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 8,178,541
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Germany | 102 38 243 | Aug 21, 2002 |
Germany | 103 12 353 | Mar 20, 2003 |
Non-Orange Book US Patents Family Members for Patent 8,178,541
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,664,232 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | ➤ Sign Up |
9,108,964 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | ➤ Sign Up |
9,321,791 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | ➤ Sign Up |
7,407,955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,178,541
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 041025 | ➤ Sign Up | |||
Argentina | 077875 | ➤ Sign Up | |||
Argentina | 087287 | ➤ Sign Up | |||
Austria | 453644 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |